Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vidarabine monophosphate is a small molecule nucleoside analog antiviral agent developed and marketed by Kaifeng Pharma (Kaifeng Mingren Pharmaceutical Co., Ltd.). It is the monophosphate derivative of vidarabine (adenine arabinoside), designed to provide significantly improved water solubility compared to the parent compound, which facilitates its administration as an injection. The drug acts as a prodrug that is intracellularly converted into its active triphosphate form. Once activated, it competitively inhibits viral DNA polymerase, thereby interfering with viral DNA synthesis and replication. In China, it is approved and marketed as a freeze-dried powder for injection for the treatment of various herpes virus infections, including herpes simplex encephalitis, cutaneous and mucosal herpes, and varicella-zoster virus infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vidarabine monophosphate.